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Results: 4885 patients were included. 56% were men and the mean age was
53. After a mean follow up of 8.6 years, 129 deaths were recorded. In multivar-
iate analysis, independent RF were age (Hazard Ratio (HR)=1.06, p<0.001, 95%
CI [1.04-1.08]), gender (HR=5.95, p<0.001, 95% CI [3.48-10.19]) , diabetes
(HR=2.49, p<0.001, 95% CI [1.49-4.16]), hypertension (HR=1.44, p=0.05, 95%
CI [1.00-2.08]), LDL-cholesterol>4 mmol/L (HR=2.04, p<0.001, 95% CI [1.40-
2.96]), smoking (HR=2.19, p<0.001, 95% CI [1.49-3.20]), lower educational
level (HR=1.81, p=0.01, 95% CI [1.18-2.79]) and resting heart rate> 65 bpm
(HR=1.54, p=0.02, 95% CI [1.06-2.24]). A good calibration was obtained
(p value NS for Hosmer-Lemeshow χ² test). The median predicted risk of mor-
tality was 6.52% and was not significantly different to the observed risk of all
cause mortality (6.60%; 95%CI [5.22%-8.34%]).
Conclusions: RHR can be used to predict all-cause mortality in primary pre-
vention and might be evaluated as a simple predictive tool in current practice. 
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Esophageal electrophysiological study (EPS) is an easy means to evaluate
the cause of palpitations in patients with negative Holter monitoring or when
cardiac event monitor is not interpretable. The purpose of study was to eva-
luate the clinical significance and the diagnosis value of inducible atrial tachy-
cardia or fibrillation (AF) by esophageal EPS. 
Methods: Esophageal EPS was performed in 159 patients, 72 males,
87 females, aged from 19 to 89 years (mean 56±16) with a normal ECG in
sinus rhythm; 35 patients had presented one episode of documented sustained
AF (group I). Remaining 124 patients had no documented AF (group II) and
were studied for not documented tachycardia (n=70), not documented tachy-
cardia associated with dizziness/syncope (n=23), unexplained stroke and
salvos of AF (n=25), wide-QRS tachycardia suspected of atrial origin (n=6).
Atrial pacing and programmed atrial stimulation with 1 and 2 extrastimuli
were performed in control state (CS) and after infusion of isoproterenol.
Patients were followed from 1 month to 13 years (mean 4±4 years).
Results: Among group I, AF was induced in 21 patients (60%). Sus-
tained AF was induced in CS (n=50) or after isoproterenol (n= 64) in all
group II patients. The follow-up indicated that 7 group I patients (21%)
had recurrent AF/atrial flutter requiring ablation, 5 patients with induced
AF and 2 with negative EPS (NS). Two group I patients (6%) with induced
AF died from a cardiac cause. Among group II, 20 patients (16%) pre-
sented documented AF/atrial flutter and 14 of them required an ablation.
Five group II patients (4%) died from a cardiac cause. The sensitivity of
esophageal EPS to reproduce AF was 60%. Its positive predictive value to
predict the occurrence of AF in symptomatic patients without documented
AF was 16%. The positive value to predict AF and cardiac death was 24%. 
Conclusions: Despite an average sensitivity for the induction of AF in
patients with documented AF, the risk of subsequent AF and/or cardiac
death was relatively high in these patients and in symptomatic patients
without documented AF but with induced AF. These patients require a
careful follow-up. 
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Atrial fibrillation (AF) and atrial flutter (AFL) are frequently associated.
The purpose of the study was to look for the effect of antiarrhythmic drugs
(AAD) on the risk of AF occurrence after radiofrequency ablation of AFL. 
Methods: 1121 patients, mean age 64±12 years, were referred for AFL
ablation. History, data of echocardiography, antiarrhythmic drug (AAD), were
collected. Patients were followed from 3 months to 10 years (mean 2.1±2.7
years). AAD was stopped after ablation except in patients with previous AF
before ablation or continued otherwise. 
Results: 857 patients received an AAD (n=637) or a betablocker (n=221). 356
patients (31.7%) had a history of AF prior to AFL ablation. Patients with AF prior
to ablation were more likely to be female (OR=1.35, CI=1.00-1.83, p=0.05), more
likely to be treated with a class I AAD (45.5% vs 7.7%), isolated or associated
with beta-blockers and more likely tended to be treated with Amiodarone (36.5%
vs. 31.2%, p=0.08). After ablation, 260 (23.2%) patients experienced AF. In mul-
tivariable model, AF prior to ablation (OR=1.90, CI=1.42-2.54, p<0.001) and
female gender (OR=1.77, CI=1.29-2.42, p<0.001) were associated with a higher
risk of AF after ablation. In patients without prior AF, Class I AAD and Amioda-
rone prior to AFL ablation were independently associated with higher risk of AF
after ablation (OR=2.11, CI=1.15-3.88, p=0.02 and OR=1.60, CI=1.08-2.36,
p=0.02 respectively). Patients with previously diagnosed AF were more likely to
be treated with a class I AAD (45.5% vs. 7.7%), isolated or associated with beta-
blockers (data not shown), and more likely tended to be treated with Amiodarone
(36.5% vs 31.2%, p=0.08).
Conclusions: AF occurrence after AFL ablation is frequent (>20%), espe-
cially in patients with a history of AF, in female patients, and in patients
treated with Class I antiarrhythmics/Amiodarone prior to AFL. The risk was
similar in patients treated with class I or III drug. In a patient referred for AFL
ablation without known AF before AFL, treated with AAD, the follow-up
should be careful because these patients appear at high risk of AF occurrence. 
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Background: Reciprocating tachycardia which occurs in patients with a
preexcitation syndrome (PS) generally is directly related to the presence of the
accessory pathway (AP) and is called atrioventricular re-entrant tachycardia
(AVRT). The purpose of the study was to evaluate the incidence of re-entrant
tachycardia of other nature among patients with a PS. 
Methods: 785 patients with paroxysmal tachycardia were admitted AP
ablation, 294 patients with a concealed AP (group I) and 491 patients with a
Wolff-Parkinson-White syndrome (WPW) (group II). Programmed atrial stim-
ulation was performed in the control state and if necessary after isoproterenol
to induce the clinical tachycardia and determine its mechanism. 
Results: AVRT was induced in 760 patients (97%), 282 of group I (96%)
and 478 of group II (97%) (NS). Atrioventricular nodal re-entrant tachycardia
(AVNRT) was induced in 13 group I patients (4.6%) and 12 group II patients
(2.5%) (NS; 0.11). In 9 group I patients (3%) and in 4 group II patients (1%)
(p<0.015), both AVRT and AVNRT were induced. In patients with only
induced AVNRT, slow pathway ablation was performed and accessory
pathway was respected because there was no inducible tachycardia using AP
and the conduction over AP was poor. These patients remained free of symp-
toms after ablation of AV node slow pathway. Among this population 3 fami-
lies were identified as having either AVRT or AVNRT. 
Conclusions: In patients with concealed or patent accessory pathway and
complaining of paroxysmal tachycardia, a careful evaluation of the mecha-
nism of tachycardia is required before ablation. Patients with concealed
conduction over an AP have more frequently an association of AVRT and
AVNRT than patients with a patent preexcitation syndrome. Rarely AVNRT
can be the only mechanism of symptoms. 
